Lexicon Pharmaceuticals Short Interest Down 4.5% in June (LXRX)
Lexicon Pharmaceuticals (NASDAQ:LXRX) was the recipient of a significant decrease in short interest during the month of June. As of June 13th, there was short interest totalling 18,236,776 shares, a decrease of 4.5% from the May 30th total of 19,087,261 shares, American Banking News.com reports. Based on an average daily volume of 1,655,679 shares, the short-interest ratio is presently 11.0 days. Currently, 3.6% of the company’s stock are sold short.
Lexicon Pharmaceuticals (NASDAQ:LXRX) opened at 1.61 on Tuesday. Lexicon Pharmaceuticals has a 1-year low of $1.25 and a 1-year high of $3.18. The stock’s 50-day moving average is $1.5 and its 200-day moving average is $1.6. The company’s market cap is $829.1 million.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.01. The company had revenue of $277.00 million for the quarter, compared to the consensus estimate of $0.12 million. Analysts expect that Lexicon Pharmaceuticals will post $-0.19 EPS for the current fiscal year.
Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.